Frankfurt
09.10.26 | 20:15
0,056 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - June 2026 | 164 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 25, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - June 2026 is... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 24.08. | Isofol Medical AB: Isofol expands the number of study sites to accelerate patient recruitment in cancer study | 199 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 24, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company includes additional clinical trial sites to the ongoing phase Ib/II study with... ► Artikel lesen | |
| 08.07. | Isofol Medical AB: Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin | 494 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 8, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the third dose level in the dose-escalation part of the phase... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026 | 485 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the "Company") held its annual general meeting (the "AGM") today. The following resolutions, in principle, were... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - March 2026 | 247 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - March 2026 is now... ► Artikel lesen | |
| 15.04. | Isofol Medical AB: Isofol optimizes the design of its phase Ib/II study following new regulatory approval | 599 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized design for the company's... ► Artikel lesen | |
| 18.03. | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | 863 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| 11.03. | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | 429 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| 24.02. | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 734 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 250 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen | |
| 13.11.25 | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | 563 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| 12.11.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2025 | 321 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January-September 2025... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,548 | +1,23 % | Valneva: Großbritannien entzieht Chikungunya-Impfstoff die Zulassung | Valneva verliert in Großbritannien die Marktzulassung für seinen Chikungunya-Impfstoff IXCHIQ. Die britische Arzneimittelbehörde MHRA hat die Genehmigung nach einer erneuten Nutzen-Risiko-Bewertung... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,800 | +4,98 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| SIRONA BIOCHEM | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,102 | -4,01 % | 740 % Kurspotenzial laut B. Riley: Cardiol Therapeutics will Kiniksa bei wiederkehrender Herzbeutelentzündung Konkurrenz machen | Bei der Behandlung der wiederkehrenden Herzbeutelentzündung (rezidivierende Perikarditis) steht eine Neuerung an, die den Markt deutlich verändern könnte. Bisher setzt die Medizin zunächst auf unspezifisch... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,151 | +5,08 % | Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up | ||
| BIOMERIEUX | 83,20 | +3,55 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,849 | 0,00 % | Morning Market Movers: Bio Green Med Solution, Solidion Technology, Indaptus Therapeutics, Merlin, Inc. See Big Swings | BEIJING (dpa-AFX) - At 7:20 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ANAPTYSBIO | 42,500 | +3,16 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update | Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli... ► Artikel lesen | |
| GENUS | 26,200 | +1,55 % | Genus PLC - Annual Report and Annual General Meeting | ||
| MEIRAGTX | 9,700 | +3,19 % | MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors | LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of... ► Artikel lesen | |
| AKESO | 12,280 | +1,49 % | Akeso, Inc.: Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer | HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,580 | +0,64 % | XTL Biopharmaceuticals Ltd.: XTL Completed the Acquisition of Psyga Bio Ltd. | expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic... ► Artikel lesen | |
| ABIONYX PHARMA | 1,532 | +4,93 % | ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply | CER-001: a distinctive manufacturing challenge to produce a full-length recombinant human apoA-I, a 243-amino-acid protein to form a biomimetic HDL particle A strategic partnership including... ► Artikel lesen | |
| MAAT PHARMA | 0,891 | -1,11 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under Review | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
07.10.2026 / 14:10 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | -1,40 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript |
Das Unternehmen ISOFOL MEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,056 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.